Cargando…

Antibody Responses 3-5 Months Post-Vaccination with mRNA-1273 or BNT163b2 in Nursing Home Residents

Detalles Bibliográficos
Autores principales:	Breznik, Jessica A., Zhang, Ali, Huynh, Angela, Miller, Matthew S., Nazy, Ishac, Bowdish, Dawn M.E., Costa, Andrew P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. on behalf of AMDA - The Society for Post-Acute and Long-Term Care Medicine. 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558841/ https://www.ncbi.nlm.nih.gov/pubmed/34736891 http://dx.doi.org/10.1016/j.jamda.2021.10.001

Ejemplares similares

Antibody Responses to Third-Dose mRNA Vaccines in Nursing Home and Assisted Living Residents
por: Zhang, Ali, et al.
Publicado: (2022)

Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study
por: Leong, Darryl P., et al.
Publicado: (2023)

Protection from Omicron Infection in Residents of Nursing and Retirement Homes in Ontario, Canada
por: Breznik, Jessica A., et al.
Publicado: (2023)

Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents
por: Montejano-Hervás, Pablo, et al.
Publicado: (2022)

Early Omicron infection is associated with increased reinfection risk in older adults in long-term care and retirement facilities
por: Breznik, Jessica A., et al.
Publicado: (2023)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose
por: Markewitz, Robert, et al.
Publicado: (2022)

Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
por: Dickerman, Barbra A., et al.
Publicado: (2021)

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
por: Thompson, Mark G., et al.
Publicado: (2021)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2022)

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

BNT162b2, mRNA-1273, et EMA : une procédure qui roule
por: Dalmat, Yann-Mickael
Publicado: (2021)

The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273
por: Markewitz, Robert, et al.
Publicado: (2022)

Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents
por: Canaday, David H., et al.
Publicado: (2021)

Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination
por: Goddard, Kristin, et al.
Publicado: (2022)

mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations
por: Carreño, Juan Manuel, et al.
Publicado: (2022)

Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2023)

Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2
por: Vollenberg, Richard, et al.
Publicado: (2022)

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
por: Anderson, Evan J., et al.
Publicado: (2022)

Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273
por: Grunau, Brian, et al.
Publicado: (2022)

Antibody maintenance and breakthrough infections 6 months after complete COVID-19 vaccination with the mRNA-1273 and BNT162b2 vaccines in hemodialysis patients
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2021)

BNT162b2, mRNA-1273 : des vaccins mis en examen à l’EMA
por: Manus, Jean-Marie
Publicado: (2021)

Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines
por: Mavrovouniotis, Ilias, et al.
Publicado: (2023)

Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients
por: Bagacean, Cristina, et al.
Publicado: (2021)

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
por: Hammer, Helly, et al.
Publicado: (2022)

Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions
por: Haq, Hannah N., et al.
Publicado: (2022)

The COVID Complex: A Review of Platelet Activation and Immune Complexes in COVID-19
por: Jevtic, Stefan D., et al.
Publicado: (2022)

Pronounced antibody elevation after SARS‐CoV‐2 BNT162b2 mRNA booster vaccination in nursing home residents
por: Chong, Yong, et al.
Publicado: (2022)

Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines
por: Naranbhai, Vivek, et al.
Publicado: (2021)

The impact of respiratory infections and probiotic use on the nasal microbiota of frail residents in long-term care homes
por: Bowdish, Dawn M.E., et al.
Publicado: (2023)

Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients
por: Haller, Maria C., et al.
Publicado: (2022)

Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia
por: Bagacean, Cristina, et al.
Publicado: (2022)

Tolerability of Coronavirus Disease 2019 Vaccines, BNT162b2 and mRNA-1273, in Patients With Thymic Epithelial Tumors
por: Ballman, Madison, et al.
Publicado: (2021)

POS-975 SEROLOGIC RESPONSE TO THE mRNA-1273 and BNT162b2 COVID-19 VACCINES IN DIALYSIS PATIENTS
por: Yau, K., et al.
Publicado: (2022)

Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
por: Puranik, Arjun, et al.
Publicado: (2022)

Myocarditis after BNT162b2 and mRNA-1273 COVID-19 vaccination: A report of 7 cases
por: Ahmed, Sirwan Khalid
Publicado: (2022)

Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines
por: Naveed, Zaeema, et al.
Publicado: (2022)

De novo vasculitis after mRNA-1273 (Moderna) vaccination
por: Anderegg, Manuel A., et al.
Publicado: (2021)

Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain
por: Fernández-Ciriza, Leire, et al.
Publicado: (2022)

Distinct glomerular disease association after vaccination with BNT162b2 and mRNA-1273: a VigiBase analysis
por: Kronbichler, Andreas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h8q3u9151npmq699ibnuhieqdp